．

Material Information - PharmaEssentia Files for an Additional Indication of Besremi (Ropeginterferon alfa-2b) for the Treatment of Essential Thrombocythemia (ET) with TFDA

Sep 5, 2025

20250905 本公司向TFDA申請新藥Ropeg新增適應症，新增適應症為ET (EN).pdf

Download